

Michael J Pontecorvo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6424459/publications.pdf>

Version: 2024-02-01

28
papers

5,116
citations

304743

22
h-index

552781

26
g-index

30
all docs

30
docs citations

30
times ranked

5175
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Hemispheric Asymmetry and Atypical Lobar Progression of Alzheimer-Type Tauopathy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2022, 81, 158-171. | 1.7 | 2 |
| 2 | Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1091-1104. | 2.6 | 17 |
| 3 | Four distinct trajectories of tau deposition identified in Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 871-881. | 30.7 | 354 |
| 4 | Methods and future directions for evaluation of Tau PET signal. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 5 | Positron Emission Tomography Imaging With [¹⁸ F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. <i>JAMA Neurology</i> , 2020, 77, 829. | 9.0 | 244 |
| 6 | The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. <i>Brain</i> , 2020, 143, 3805-3815. | 7.6 | 65 |
| 7 | Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer's disease pathology: a clinicopathological study. <i>EJNMMI Research</i> , 2020, 10, 65. | 2.5 | 25 |
| 8 | A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia. <i>Brain</i> , 2019, 142, 1723-1735. | 7.6 | 156 |
| 9 | Tau Positron-Emission Tomography in Former National Football League Players. <i>New England Journal of Medicine</i> , 2019, 380, 1716-1725. | 27.0 | 165 |
| 10 | Flortaucipir F 18 Quantitation Using Parametric Estimation of Reference Signal Intensity. <i>Journal of Nuclear Medicine</i> , 2018, 59, 944-951. | 5.0 | 73 |
| 11 | Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 825-837. | 6.4 | 40 |
| 12 | Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. <i>Brain</i> , 2017, 140, aww334. | 7.6 | 257 |
| 13 | Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 4. | 6.2 | 134 |
| 14 | Imaging characteristics and safety of florbetapir (18F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease. <i>Annals of Nuclear Medicine</i> , 2015, 29, 570-581. | 2.2 | 10 |
| 15 | DT-02-03: A randomized, controlled, multicenter, international study of the impact of florbetapir (18) Tj ETQq1 1 0.784314 rgBT /Ove | | |
| 16 | Quantification of 18F-florbetapir PET: comparison of two analysis methods. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 725-732. | 6.4 | 25 |
| 17 | ¹⁸ F-Florbetapir PET in Patients with Frontotemporal Dementia and Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2015, 56, 386-391. | 5.0 | 41 |
| 18 | A Semiautomated Method for Quantification of F 18 Florbetapir PET Images. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1736-1741. | 5.0 | 61 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Comparing positron emission tomography imaging and cerebrospinal fluid measurements of ^{125}I -amyloid. <i>Annals of Neurology</i> , 2013, 74, 826-836. | 5.3 | 320 |
| 20 | Amyloid deposition detected with florbetapir F 18 (^{18}F -AV-45) is related to lower episodic memory performance in clinically normal older individuals. <i>Neurobiology of Aging</i> , 2013, 34, 822-831. | 3.1 | 118 |
| 21 | Potential Impact of Amyloid Imaging on Diagnosis and Intended Management in Patients With Progressive Cognitive Decline. <i>Alzheimer Disease and Associated Disorders</i> , 2013, 27, 4-15. | 1.3 | 109 |
| 22 | Amyloid- ^{125}I assessed by florbetapir F 18 PET and 18-month cognitive decline. <i>Neurology</i> , 2012, 79, 1636-1644. | 1.1 | 206 |
| 23 | Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects. <i>Journal of Nuclear Medicine</i> , 2012, 53, 378-384. | 5.0 | 321 |
| 24 | Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid- ^{125}I plaques: a prospective cohort study. <i>Lancet Neurology</i> , The, 2012, 11, 669-678. | 10.2 | 674 |
| 25 | PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2011, 3, 11. | 6.2 | 34 |
| 26 | Use of Florbetapir-PET for Imaging ^{125}I -Amyloid Pathology. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 275. | 7.4 | 927 |
| 27 | In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease with ^{18}F -AV-133. <i>Journal of Nuclear Medicine</i> , 2010, 51, 223-228. | 5.0 | 122 |
| 28 | In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand ^{18}F -AV-45 (Florbetapir F 18). <i>Journal of Nuclear Medicine</i> , 2010, 51, 913-920. | 5.0 | 607 |